Novel Approaches to Target MECOM/EVI1 in AML
ConditionAML, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Eligibility criteria
Qualifiers
AML with MECOM or atypical 3q26 rearrangements.
Age ≥18.
Signed written informed consent according to ICH/EU/GCP and national local laws.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov